Introduction
Sleep-disordered breathing (SDB) is a prevalent condition characterized by repetitive complete or partial upper airway collapse resulting in intermittent hypoxemia and sympathetic nervous system activation with attendant adverse cardiovascular outcomes.
Studies have demonstrated an association between SDB and cardiovascular outcomes including hypertension, stroke and heart failure (1) (2) (3) (4) . Recent longitudinal data have brought to light the increased risk of cardiovascular mortality associated with SDB (5-7). Literature also supports an increased risk of death in those with SDB during the midnight-6AM hours compared to non-sleep apneics (8) . The mechanisms of SDB-associated cardiovascular disease and mortality are uncertain;
however, these may involve chronic SDB-induced atherothrombotic disease and potentially superimposed, more immediate processes such as acute vascular thrombosis/infarction.
Atherothrombosis of the vasculature, including the coronary and cerebral vessels, is considered a disorder of hemostasis, inflammation, endothelial dysfunction and lipid metabolism. We chose to focus on the role of thrombosis in SDB by examining the relation of SDB and plasminogen activator inhibitor-1 (PAI-1), a molecule which inhibits fibrinolysis by inactivation of tissue plasminogen activator given its described contribution to atherothrombotic events and associated risk of recurrent myocardial infarction (9) (10) (11) . PAI-1 levels have been shown to vary with measures of hypoxemia (12, 13) as well as sympathetic nervous system activation (14) , both known consequences of SDB. Although some data suggest increased PAI-1 levels in those with SDB (15, 16) and improvement with SDB treatment (17), these studies involved small sample sizes and individuals referred to sleep centers (15, 16) , may have inadequately controlled for confounding factors (15) , lacked a control group (17) and did not examine diurnal variability. We also investigated the association of SDB with fibrinogen given its role in clot formation and association with coronary artery disease (18). Several small studies have identified an association with fibrinogen and SDB; however, limitations of these studies include small sample sizes, lack of clarity regarding whether these relationships are independent of obesity and lack of a comparison group.(19, 20) D-dimer is a cross-linked fibrin degradation fragment which is highly sensitive in the detection of venous thromboembolic disease and may identify abnormalities of thrombosis in both the venous and arterial systems (21-23). The literature regarding an association between SDB and D-dimer is inconsistent (16, 17, 24 ).
In the current study, we report cross-sectional associations between SDB and thrombotic measures from the Cleveland Family Study, a cohort established to investigate the risk factors and consequences of SDB, which involves individuals with a wide spectrum of SDB and incorporates a collection of selective measures of evening and morning measures of thrombosis. The wide range of SDB severity in this sample provided an opportunity to explore the nature of the dose-response association between apnea hypopnea index (AHI) and pro-thrombotic markers, in particular at the low levels of SDB common in the community which have been associated with an increased risk of cardiovascular disease (3) . Some of the results of this work have been previously reported in the form of an abstract. (25)
Methods

Study Population
The initial Cleveland Family Study cohort was assembled by identifying affected families with a proband with diagnosed sleep apnea, and neighborhood controls were also recruited. Recruitment and data collection methods have been previously described (22). The current report involves subjects participating in a clinical laboratorybased examination conducted between 2001-2006 designed to identify cardiovascular risk factors associated with SDB.
Data Collection
Testing was conducted in the Dahms Clinical Research Unit (Cleveland, OH)
after obtaining Institutional Review Board approval and written informed consent from each participant. Height was measured using a rigid stadiometer, and weight with a calibrated digital scale using standardized methods, and these measures were used to calculate body mass index, BMI (kg/m 2 ). Venous blood was sampled between 22:00 and 23:00 in the supine position prior to sleep onset. Blood was again drawn, supine, between 7:00-8:00 the next morning after overnight polysomnography and an overnight fast. After centrifuging and aliquoting using standardized protocols, samples were stored at -80°C until assayed at the University of Vermont Laboratory for Clinical Biochemistry Research. PAI-1 (ng/ml), fibrinogen (mg/dl) and D-dimer (ng/ml) were assayed. PAI-1 was measured by a two-site ELISA (26) using an assay that was sensitive to free PAI-1 (both latent and active), but not PAI-1 in complex with tissue plasminogen activator. Fibrinogen concentrations were quantified by the STa-R automated coagulation analyzer (Diagnostica Stago; Parsippany, NJ) which utilizes the clotting method developed by Clauss (27) in which the level of fibrinogen is directly correlated to the clotting time of a diluted plasma sample in the presence of excess thrombin (27) . D-dimer was quantified with the STa-R analyzer using an immunoturbidometric assay (Liatest D-DI; Diagnostica Stago, Parsippany, NJ). Timing of the blood draws, the draw procedure and sample processing were carefully monitored and protocols strictly followed to prevent contamination by platelets (28, 29) . Analytical coefficients of variation for the assays were: 3.5% for PAI-1, 4.0% for fibrinogen and 1%
for D-dimer.
Overnight 14-channel polysomnography was performed using the Compumedics E-Series System (Abbotsford, Australia). Studies were scored using standard approaches (30, 31) . Apneas and hypopneas were defined using Sleep Heart Health Study criteria, modified to include nasal pressure signal. Hypopneas were identified as a discernible decline in respiratory effort (from inductive respiratory bands) or airflow (from thermocouple or nasal pressure) for >10 seconds associated with a ≥3% oxygen desaturation. The apnea hypopnea index (AHI) was used to assess SDB severity, and was defined as the number of respiratory events (apneas and hypopneas) per hour of sleep with the vast majority of apneas categorized as obstructive.
Statistical Analysis
Standard descriptive statistics were used to describe the study sample.
Continuous and categorical variables were compared between subjects with AHI < 15
and AHI ≥ 15 using Wilcoxon and Pearson chi-squared tests respectively.
The primary outcomes examined were morning and evening PAI-1 (to capture known diurnal variability in PAI-1), morning fibrinogen and morning D-dimer levels. To satisfy model assumptions, morning and evening PAI-1 and D-dimer levels were log transformed prior to model fitting.
To model the association between AHI and each thrombosis marker, linear mixed models with a compound symmetric covariance structure to account for withinfamily correlation were used. To assess the functional form of AHI relative to markers of thrombosis, a restricted cubic spline model was initially fit and showed an approximate linear threshold effect at a AHI of 15. Consequently, a piecewise linear mixed model with one knot at AHI=15 was used. To facilitate interpretation, the parameter estimates from these models were used to estimate the relative (geometric) mean change in level of PAI-1 or D-dimer or the mean change in morning fibrinogen for each 5-unit AHI change.
To examine the effect of possible confounders on the association between AHI and each thrombosis marker, two multivariable models were also fit. The association between hypoxia [percentage of total sleep time <90% oxygen saturation (dichotomized at 2% given its skewed distribution)] and arousal index (dichotomized at 15) with each thrombotic marker was also examined. To further examine any confounding influence of cardiac/cerebrovascular disease or hypertension, sensitivity analyses were performed excluding those participants with these respective disorders.
All tests were performed using SAS v 9.2 (SAS Institute Inc., Cary, NC) for analyses and R 2.9.2 for the graphs.
Results
Primary Analyses
Of the 735 participants in the study, the analyses were restricted to participants >16 years of age (n = 644) and without severe chronic health conditions such as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis and liver or renal disease African American. As expected, there was a higher percentage of males and subjects with obesity, diabetes mellitus, hypertension and cardiac or cerebrovascular disease in those with AHI>15 compared to those with AHI<15.
To initially examine the association between AHI and each of the markers, an unadjusted mixed model was fit using a restricted cubic smoothing spline to model AHI.
An increase in AHI was associated with increases in the levels of morning and evening log PAI-1 as well as morning and evening fibrinogen until a threshold AHI of 15 was reached, at which point there appeared to be a plateau (Figures 1 and 2 ). In contrast, no association was observed between D-dimer levels and AHI. Table 2 presents the results from the piecewise linear mixed models that were developed to investigate the association between AHI and morning and evening PAI-1
Morning and Evening Plasminogen Activator Inhibitor-1
and After adjusting for potential confounders, including BMI, cardiovascular factors and medications (Model 2), the association with lower levels of SDB (AHI<15) and morning PAI-1 was attenuated, but persisted such that the mean of morning PAI-1 increased, on average, by 12% (95% CI: (5%, 20%); p<0.001) per 5-unit AHI increase.
With respect to evening PAI-1 levels and AHI, the results were similar to that of morning PAI-1. For evening PAI-1, Model 1 demonstrated that at levels of AHI < 15, the mean of evening PAI-1 increased by 24% (95% CI: (14%, 36%); p<0.001) per 5-unit AHI increase. Alternatively, at levels of AHI ≥ 15, the relative mean change in morning PAI-1 remained relatively the same (p=0.46) per 5-unit AHI increase. The test of the piecewise linear association between AHI and evening PAI-1 was significant (p<0.001),
indicating that for a 5-unit increase in AHI, the relative mean change in evening PAI-1 when AHI < 15 was significantly different from the relative mean change in evening PAI-1 when AHI ≥ 15. In Model 2, after adjusting for potential confounders, the association with lower levels of SDB (AHI<15) and evening PAI-1 was attenuated (similar to associations noted with morning levels), but persisted such that when AHI increased by 5 units, the mean in evening PAI-1 increased by 11% (95% CI: (2%, 20%); p=0.02).
Given the biologic plausibility that morning levels of thrombotic markers may be increased due to overnight SDB-associated physiological stressors, and known diurnal variability in PAI-1, an analysis of PAI-1 morning levels was also performed after further adjusting for PAI-1 evening levels (Model 3). In this case, there remained a statistically significant association between morning PAI-1 and mild degrees of SDB (AHI<15) such that when AHI increased by 5 units, the mean in morning PAI-1 increased by 10% (95% CI: (3%, 17%); p=0.002).
Sensitivity analyses of morning and evening PAI-1 excluding those participants with cardiac/cerebrovascular disease (n=475) or excluding those with hypertension (n=342) revealed that unadjusted and fully adjusted results were consistent with those presented in the primary analyses. Tables are included in the on-line supplement.
There was no statistically significant association between percentage of sleep time <90% oxygen saturation or arousal index with both morning and evening PAI-1 in the partially or fully adjusted models.
Morning and Evening Fibrinogen
Although initially both morning and evening levels of fibrinogen were measured, an interim analysis showed these analyses to be highly correlated (r=0.87; n=397); therefore, primary analyses reported results for morning fibrinogen only. Table 3 presents the results from the piecewise linear mixed models that were developed to investigate the association between AHI and morning fibrinogen levels and Diurnal variation of PAI-1 activity has been reported such that higher PAI-1 levels occur in the morning (32-34). We observed both diurnal variation as well as variation of both evening and morning PAI-1 levels in association with increased AHI levels from 0 to 15. This suggests that overall daily levels of PAI-1 are elevated in association with mild to moderate SDB. Also, after adjusting for evening PAI-1 in addition to other covariates, the relative mean change in morning PAI-1 per 5-unit AHI increase was not substantively attenuated (10%) compared to the model that did not adjust for evening PAI-1 (11%). The persistence of an association between morning PAI-1 levels and incremental increases in AHI even after adjusting for evening levels in conjunction with its relatively short half-life of 2-5 hours (35), suggests that morning PAI-1 may be a useful marker of overnight SDB-related stress. We have also observed similar relationships of SDB severity and morning soluble interleukin-6 receptor levels, though not with interleukin-6 levels(36).
Fibrinogen has been identified as a risk factor for cardiovascular disease likely due to multiple mechanisms including: binding to activated platelets via glycoprotein IIb/IIIa, and contributing to platelet aggregation, promotion of fibrin formation, enhancing plasma viscosity and serving as an acute-phase reactant. In the current study, morning fibrinogen levels were observed to increase relative to increases in AHI in those with mild to moderate SDB. Prior research has shown that individuals with ischemic stroke and SDB have higher levels of fibrinogen which correlates with SDB and hypoxia severity (20).
Unlike PAI-1 and fibrinogen, D-dimer did not demonstrate a significant association with mild to moderate SDB, which is consistent with previously published findings. D-dimer is a breakdown product of a stabilized fibrin mesh and has been measured clinically as a highly sensitive marker of venous thromboembolism and disseminated intravascular coagulation (21, 23). Since elevations may occur generally with aging and in settings of venous disease (the latter of which has not been commonly reported in association with SDB), its use as a marker of SDB may be limited.
Perhaps the most interesting aspect of our findings was evidence for a plateau effect at a AHI of approximately 15. There is much uncertainty regarding thresholds and dose-response relationships between indices of SDB and various health outcomes.
Understanding the levels of SDB that are associated with increased risk of cardiovascular disease is needed to most effectively target groups likely to benefit from SDB interventions. Most clinic-based samples have reported increased risk of adverse cardio-metabolic outcomes at the severe levels of SDB common in referred samples (5, 37) . However, our findings are consistent with the cross-sectional data from the Sleep Heart Health Study, which also showed an increase in the prevalence of cardiovascular disease at low levels of SDB, with further risk plateauing at an AHI of approximately 11 (3) . It is possible that there is a physiologic threshold effect of hypoxic and sympathetic nervous system surges on the thrombotic milieu such that more severe levels of SDB may not be associated with progressive increases in thrombotic biomarkers. Counterregulatory mechanisms may potentially manifest after a certain level of SDB-physiologic burden is realized, such that thrombotic risk may plateau, and therefore higher levels of SDB may not be associated with a graded increase in thrombotic risk. Although clinical trials are needed to shape intervention guidelines, these data suggest that individuals with even modest levels of SDB (which describe a large proportion of the adult population) may have an enhanced pro-thrombotic biochemical profile, increasing their cardiovascular disease risk.
In addition to examining the AHI as the primary metric of SDB exposure, we also Compared to time in desaturation, the AHI, may more specifically measure stresses associated with intermittent hypoxia, which may the relevant stimulus for adverse inflammatory/pro-thrombotic responses. Although arousals may be associated with surges in sympathetic nerve activity; the arousal index, which reflects sleep disruption occurring with or without airway obstruction, may not reflect SDB pro-thrombotic stresses as well as the AHI, which reflects disturbances specific to airway occlusion.
Several study limitations need to be acknowledged. Given the cross-sectional design, causality is uncertain. Inferences regarding dose-response relationships at the highest levels of the AHI distribution were based on a relatively modest sample size and it is possible that more significant associations with higher levels of AHI or levels of hypoxia with each biomarker may have been observed had the sample included larger numbers of individuals with severe SDB. Although we adjusted for many known confounders, residual confounding nonetheless may have influenced our results. Both PAI-1 and fibrinogen have been implicated in both incident and recurrent cardiovascular events. (9, 38) Our results were primarily attributed to associations observed in individuals without established cardiac or cerebrovascular disease, and thus, best address SDB as a putative antecedent risk factor for cardiovascular disease. Our findings may differ from those of other epidemiological studies demonstrating increased cardiovascular risk and mortality (6, 7) due to the relatively young age of our cohort members. Strengths of the current study include the moderately large sample size, rigorous collection of data, collection of evening and morning levels to assess diurnal variability and analysis of data from a non-referral sample. This is the largest study to date to examine the associations between fibrinogen and PAI-1 relative to SDB.
In summary, these data suggest that, at low modest levels of SDB, incremental increases in AHI are associated with increases in levels of two pro-thrombotic biomarkers associated with cardiovascular disease. Future directions include exploring whether treatment of even mild to moderate levels of SDB improves biomarkers of thrombosis, and performing further work to understand the specific pathways and pathobiology of SDB-related increased risk of thrombosis. 
